The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines –NEW YORK, March 18, ...

China NMPA approves Akeso's penpulimab for first-line treatment of nasopharyngeal cancer: Hong Kong Tuesday, March 18, 2025, 17:00 Hrs [IST] Akeso Inc., a biopharmaceutical compan ...

Cancer impacts millions globally, with lifestyle choices such as smoking, diet, physical activity, alcohol consumption, sun ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Chen, F. (2025) Advances in the Application of Deep Learning in Prognostic Models for Non-Small Cell Lung Cancer. Health, 17, ...

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics ...

When diagnosing lung metastases and second primary lung cancer in patients with head and neck cancer, low-dose CT leads to better sensitivity than chest x-ray but does not lead to improved overall ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

Skin cancer is the most common cancer in the United States and a significant health issue, with millions of non-melanoma cases and tens of thousands of melanomas diagnosed annually. Furthermore, ...